Is DOCS a buy according to AI stock analysis?

DOCS AI stock analysis does not label the stock an automatic buy. The setup is most attractive for investors who believe Doximity can sustain high margins and re-accelerate growth through AI products, while price-sensitive buyers may want to see a confirmed technical breakout above resistance levels before committing capital.

What is the DOCS AI stock forecast?

The DOCS AI stock forecast uses scenarios rather than a fixed target. Based on the July 12, 2026 data cutoff, the three-year framework points to a bearish range near $14 to $18, a base range near $24 to $28, and a bullish range near $33 to $40, depending on growth rates and market valuation multiples.

What technical levels matter for DOCS?

The key DOCS technical levels are near support around $19.50 to $21.00, secondary support at the 52-week low of $17.00 to $17.50, resistance around $24.50 to $26.00, and the 50-day moving average near $23.80. A close below $17 would weaken the base-building thesis.

Can AI predict DOCS stock price?

No, AI cannot reliably predict stock prices. AI can organize fundamentals, technical levels, valuation math, and risk factors, but DOCS stock can move quickly because of earnings results, guidance changes, pharma marketing trends, healthcare regulation, AI product adoption metrics, and broader market sentiment toward growth stocks.

How should I use this DOCS AI trading strategy?

Use this DOCS AI trading strategy as a research checklist, not personal advice. Pair technical confirmation with revenue growth trends, FCF generation, AI product traction, cash balance, and insider trading signals, then define position size and invalidation before acting.

What makes Doximity different from other healthcare IT companies?

Doximity operates the largest physician-only digital network in the US with roughly 80% of all US doctors as verified members. Its combination of network effects, HIPAA-compliant workflow tools (telehealth, scheduling, AI assistant, AI scribe), and targeted pharma marketing platform creates a differentiated vertical-specific platform that general-purpose tools cannot easily replicate.

Doximity, Inc. research snapshot

DOCS AI Stock Analysis

DOCS AI stock analysis currently reads Doximity as a high-margin healthcare technology platform with strong physician network effects, zero debt, significant cash reserves, and improving free cash flow. The AI view is not a single price prediction: the business quality is supported by its dominant position among US medical professionals, high switching costs, and recurring revenue, while the entry price depends on whether revenue growth can re-accelerate, margins hold, and the market re-rates the stock from its current low valuation relative to cash flow.

Current price

$21.77

Market cap

$3.98 billion

AI score

60 / 100

Rating

Healthcare tech, valuation watch

Trend status

Recovering from lows, range-bound with upside potential

Data cutoff (updated weekly)

July 12, 2026

Informational use only. This page is not investment advice.

Research quality check

information Richness: B-level information richness. Doximity is a public company since 2021 with analyst coverage from about 20 analysts, SEC filings, and quarterly earnings. However, it has less coverage depth than mega-cap tech stocks, and the health-tech vertical has fewer comparable companies.
bias Check: The main AI research risk is the sharp price decline from $76 to $21 creating recency bias. This page separates the underlying business quality from stock price momentum and focuses on fundamental drivers like revenue growth, margins, cash generation, and network effects.
ai Confidence: High for reported revenue, net income, cash balance, and market data. Medium for forecast ranges because revenue growth trajectory, AI product adoption, and pharma marketing budgets are harder to predict with precision.
investment Certainty: Medium. The asset-light model, zero-debt balance sheet, and strong FCF are attractive, but growth deceleration from the COVID-era peak, the need for AI product monetization, and concentration in healthcare marketing spending add uncertainty.

Quick verdict table

Dimension	Conclusion	Confidence
Business quality	Doximity operates a leading digital platform connecting US medical professionals, with ~80% of US physicians as members. Its network effects and workflow tools create a defensible position.	Medium-high
Moat	The moat comes from physician network effects, workflow integration (telehealth, scheduling, AI tools), regulatory compliance (HIPAA), and brand trust. Few competitors have similar physician adoption.	Medium
Management	Founder-led with Jeff Tangney as CEO since 2010. Management has maintained a debt-free balance sheet, generated strong FCF, and invested in AI capabilities (Ask, Scribe). Capital allocation has been prudent.	Medium-high
Financial trend	FY2026 revenue was about $645 million with net income of $196 million. Gross margins are ~89%, operating margins ~39%, and FCF margin is healthy at ~40%. Revenue growth is decelerating from COVID-era peaks.	High
Valuation	At $21.77, DOCS trades at 22.2x trailing earnings, 15.2x forward earnings, 6.7x sales, and 15.6x FCF. The PEG ratio of 0.59 suggests value relative to growth.	Medium
Technical trend	DOCS has declined sharply from its 52-week high of $76.51 to $21.77. It is trying to base near $17-22 range. Moving averages remain in a bearish configuration but momentum shows signs of stabilization.	Medium
Risk level	Risk is moderate. Key risks include revenue concentration in pharma marketing, AI product execution, healthcare regulation, and the ability to sustain growth rates as the platform matures.	Medium-high
AI confidence	The data set is adequate for a mid-cap healthcare tech company. Financial statements are clear, but forward-looking assessment depends on growth rate assumptions and product adoption curves.	Medium
Investment certainty	Below-average certainty. The business model is sound but valuation depends heavily on growth re-acceleration. A margin of safety exists at current prices if growth stabilizes, but downside remains if revenue growth slows further.	Medium-low

DOCS AI stock forecast

DOCS AI Stock Forecast Scenarios

The DOCS AI stock forecast should be read as scenario analysis, not a guaranteed target. Using a July 12, 2026 data cutoff, a $21.77 price, and trailing EPS of $0.98, the tested three-year range is roughly $17 in a bearish case, $26 in a base case, and $37 in a bullish case.

Bullish case

$33 to $40

More likely if Doximity re-accelerates revenue growth above 15% through AI product adoption (Ask, Scribe), expands pharma marketing budgets, and the market re-rates the stock to a 25x+ forward PE.

Base case

$24 to $28

More likely if revenue grows at 8-12% annually, margins remain strong, FCF generation continues, and the stock trades at a 18-22x forward PE reflecting steady but slower growth.

Bearish case

$14 to $18

More likely if revenue growth dips below 5%, AI product monetization disappoints, pharma marketing spending contracts, or competitive pressure from larger healthcare IT platforms intensifies.

DOCS AI technical analysis

DOCS AI Technical Analysis

DOCS AI technical analysis shows a stock in a prolonged downtrend since its 2021 highs, now attempting to form a base near multi-year lows. Around the July 12, 2026 data cutoff, DOCS traded near $21.77, down 72% from its 52-week high of $76.51. The stock has recently broken above its 20-day moving average but remains below its 50-day and 200-day MAs, indicating the primary trend is still bearish.

Level	Value	Why it matters
Current price	$21.77	Recent market data around the July 10, 2026 close, cross-checked against Google Finance and Yahoo Finance reporting.
Near support	$19.50 to $21.00	Recent consolidation zone after the sharp sell-off. The stock bounced from near $17.15 and is testing higher levels.
Secondary support	$17.00 to $17.50	The 52-week low area. A break below this level would suggest further downside toward the IPO price area.
Near resistance	$24.50 to $26.00	Prior breakdown level and a potential supply zone. A close above $26 would be a meaningful short-term breakout.
50-day moving average	About $23.80	Investing.com cited DOCS 50-day MA near $23.80. Price below this level keeps the short-term trend bearish.
200-day moving average	About $38.50	The 200-day MA is well above current price, confirming the long-term downtrend. A cross above would be a major trend change.
Momentum	RSI about 42-48 range	RSI is neutral after recovering from oversold levels, suggesting the selling pressure has eased but buying conviction is not yet strong.
Volume and volatility	Avg. volume about 3.6M, beta 1.30	Recent volume spikes on news and earnings suggest continued interest. Higher beta means larger moves in both directions.
Invalidation	Close below $17.00	A decisive break below the 52-week low would invalidate the base-building narrative and suggest a new leg down.

DOCS AI trading strategy

DOCS AI Trading Strategy Framework

The DOCS AI trading strategy below is a research framework for planning, not personal investment advice. It combines healthcare tech fundamentals, cash flow analysis, AI product momentum, and technical confirmation.

Trend-following setup

Currently not applicable in a clear uptrend. For trend-following, wait for DOCS to reclaim its 50-day MA ($23.80) and break above the $26 resistance zone on strong volume while maintaining FCF growth and revenue stability.

Define the invalidation level before entry. A close back below $20 or a failed breakout at $26 would keep the stock in a range-bound pattern rather than a new uptrend.

Mean-reversion setup

If DOCS pulls back toward the $17-19 range without a revenue guidance cut, AI product failure, or balance sheet deterioration, compare the forward PE, FCF yield, and cash position before assuming value. The $748M cash pile provides a valuation floor.

Avoid catching a falling knife if the fundamental thesis is breaking. A close below $17 with expanding volume can signal that competitive or regulatory risk is outpacing value.

Fundamental monitor

Track quarterly revenue growth rate, net dollar retention, AI product adoption metrics (Ask, Scribe), pharma marketing spend trends, operating margin trajectory, FCF conversion, and cash balance deployment.

Re-run the scenario range after earnings, guidance updates, analyst downgrades, or a major product announcement. Watch for insider buying or selling patterns as sentiment signals.

Investment research summary

Four-master Research Compression

Business essence

Doximity is the largest digital platform connecting US medical professionals. Customers (pharma companies, health systems, and doctors themselves) pay because the platform provides unmatched access to the physician community, HIPAA-compliant workflow tools, and targeted marketing reach that cannot be easily replicated.

Moat

The moat is built on physician network effects (~80% of US doctors as members), workflow integration (telehealth, scheduling, credentialing), regulatory compliance (HIPAA), and brand trust. Competitors face high switching costs because doctors integrate Doximity into their daily workflow.

Munger risk inversion

The thesis fails if Doximity loses physician engagement to competing platforms, AI tools like Ask and Scribe fail to monetize, pharma marketing budgets shift away from digital platforms, larger tech companies (Microsoft, Google) enter healthcare with compliant solutions, or the company misallocates its $748M cash pile.

Management

Founder-CEO Jeff Tangney has led the company since 2010, maintaining a debt-free balance sheet and strong cash generation. Key decisions include the pivot to AI-powered tools (Ask, Scribe) and maintaining high margins. Management incentives appear aligned with shareholders through significant insider ownership.

Industry trend

Healthcare digitization and AI adoption are secular trends that benefit Doximity. The shift from in-person to digital pharma marketing, growing demand for telehealth, and AI-assisted clinical workflows all support the thesis. However, Doximity must fend off competition from larger platforms and vertical-specific startups.

Valuation and margin of safety

At about $21.77, DOCS is not distressed but has compressed significantly. The margin of safety depends on whether revenue can sustain 8-12% growth, whether AI products create a new growth vector, and whether the market values the strong FCF yield and zero-debt balance sheet. The $748M cash balance (~$4/share) provides a tangible asset floor.

Source-backed data

DOCS Data Table

Every metric below includes a source and last verification date.

Metric	Value	Source	Last verified
DOCS price	$21.77	Yahoo Finance and Google Finance market data	July 12, 2026
Market capitalization	$3.98 billion, verified from $21.77 x 182.87M shares	Yahoo Finance and financial_rigor.py	July 12, 2026
Shares outstanding	182.87 million shares	Yahoo Finance, cross-checked with WallStreetZen	July 12, 2026
TTM revenue	$644.86 million	Yahoo Finance financials, cross-checked with Google Finance	July 12, 2026
TTM net income	$196.05 million	Yahoo Finance financials, confirmed via income statement review	July 12, 2026
TTM EPS	$0.98	Yahoo Finance statistics, cross-checked with financial_rigor.py	July 12, 2026
Cash and equivalents	$748.6 million at latest quarter	Yahoo Finance balance sheet data	July 12, 2026
Total debt	Negligible (debt/equity ratio ~0.18)	Yahoo Finance statistics, cross-checked with WallStreetZen	July 12, 2026
Levered free cash flow	$255.26 million (TTM)	Yahoo Finance statistics	July 12, 2026
Gross margin	89.1%	WallStreetZen financial data	July 12, 2026

Frequently Asked Questions

View the AI Stock Picker Explore healthcare tech stocks Build an AI trading strategy Read the VEEV AI stock analysis

This DOCS AI stock analysis is an informational research tool only. It is not investment advice, tax advice, or a recommendation to buy, sell, or hold Doximity stock. Forecast scenarios are based on available public data, valuation assumptions, and technical levels as of the stated cutoff date and can be wrong.